These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 21247380

  • 1. Peptidyl prolyl isomerase, Pin1 is a potential target for enhancing the therapeutic efficacy of etoposide.
    Mathur R, Chandna S, N Kapoor P, S Dwarakanath B.
    Curr Cancer Drug Targets; 2011 Mar; 11(3):380-92. PubMed ID: 21247380
    [Abstract] [Full Text] [Related]

  • 2. Phosphorylation-dependent proline isomerization catalyzed by Pin1 is essential for tumor cell survival and entry into mitosis.
    Rippmann JF, Hobbie S, Daiber C, Guilliard B, Bauer M, Birk J, Nar H, Garin-Chesa P, Rettig WJ, Schnapp A.
    Cell Growth Differ; 2000 Jul; 11(7):409-16. PubMed ID: 10939594
    [Abstract] [Full Text] [Related]

  • 3. [Recent advances in the study of pin1 and its inhibitors].
    Zhang CJ, Zhang ZH, Xu BL, Wang YL.
    Yao Xue Xue Bao; 2008 Jan; 43(1):9-17. PubMed ID: 18357725
    [Abstract] [Full Text] [Related]

  • 4. Juglone, an inhibitor of the peptidyl-prolyl isomerase Pin1, also directly blocks transcription.
    Chao SH, Greenleaf AL, Price DH.
    Nucleic Acids Res; 2001 Feb 01; 29(3):767-73. PubMed ID: 11160900
    [Abstract] [Full Text] [Related]

  • 5. The rotamase Pin1 is up-regulated, hypophosphorylated and required for cell cycle progression in head and neck squamous cell carcinomas.
    Wiegand S, Dakic B, Rath AF, Makarova G, Sterz C, Meissner W, Bette M, Adamkiewicz J, Müller-Brüsselbach S, Müller R, Werner JA, Mandic R.
    Oral Oncol; 2009 Oct 01; 45(10):e140-9. PubMed ID: 19502098
    [Abstract] [Full Text] [Related]

  • 6. Multisite phosphorylation of Pin1-associated mitotic phosphoproteins revealed by monoclonal antibodies MPM-2 and CC-3.
    Albert AL, Lavoie SB, Vincent M.
    BMC Cell Biol; 2004 Jun 01; 5():22. PubMed ID: 15171797
    [Abstract] [Full Text] [Related]

  • 7. Pin1 Inhibitor Juglone Exerts Anti-Oncogenic Effects on LNCaP and DU145 Cells despite the Patterns of Gene Regulation by Pin1 Differing between These Cell Lines.
    Kanaoka R, Kushiyama A, Seno Y, Nakatsu Y, Matsunaga Y, Fukushima T, Tsuchiya Y, Sakoda H, Fujishiro M, Yamamotoya T, Kamata H, Matsubara A, Asano T.
    PLoS One; 2015 Jun 01; 10(6):e0127467. PubMed ID: 26039047
    [Abstract] [Full Text] [Related]

  • 8. Proteasomal degradation of human peptidyl prolyl isomerase pin1-pointing phospho Bcl2 toward dephosphorylation.
    Basu A, Das M, Qanungo S, Fan XJ, DuBois G, Haldar S.
    Neoplasia; 2002 Jun 01; 4(3):218-27. PubMed ID: 11988841
    [Abstract] [Full Text] [Related]

  • 9. Phosphorylation-specific prolyl isomerase Pin1 as a new diagnostic and therapeutic target for cancer.
    Finn G, Lu KP.
    Curr Cancer Drug Targets; 2008 May 01; 8(3):223-9. PubMed ID: 18473735
    [Abstract] [Full Text] [Related]

  • 10. Prolyl-isomerase Pin1 impairs trastuzumab sensitivity by up-regulating fatty acid synthase expression.
    Yun HJ, Kim JY, Kim G, Choi HS.
    Anticancer Res; 2014 Mar 01; 34(3):1409-16. PubMed ID: 24596388
    [Abstract] [Full Text] [Related]

  • 11. Peptidyl-prolyl isomerase Pin1 markedly enhances the oncogenic activity of the rel proteins in the nuclear factor-kappaB family.
    Fan G, Fan Y, Gupta N, Matsuura I, Liu F, Zhou XZ, Lu KP, Gélinas C.
    Cancer Res; 2009 Jun 01; 69(11):4589-97. PubMed ID: 19458071
    [Abstract] [Full Text] [Related]

  • 12. Pin1 as an anticancer drug target.
    Xu GG, Etzkorn FA.
    Drug News Perspect; 2009 Sep 01; 22(7):399-407. PubMed ID: 19890497
    [Abstract] [Full Text] [Related]

  • 13. Pin1 deficiency causes endothelial dysfunction and hypertension.
    Chiasson VL, Munshi N, Chatterjee P, Young KJ, Mitchell BM.
    Hypertension; 2011 Sep 01; 58(3):431-8. PubMed ID: 21810655
    [Abstract] [Full Text] [Related]

  • 14. The peptidyl-prolyl isomerase Pin1 up-regulation and proapoptotic function in dopaminergic neurons: relevance to the pathogenesis of Parkinson disease.
    Ghosh A, Saminathan H, Kanthasamy A, Anantharam V, Jin H, Sondarva G, Harischandra DS, Qian Z, Rana A, Kanthasamy AG.
    J Biol Chem; 2013 Jul 26; 288(30):21955-71. PubMed ID: 23754278
    [Abstract] [Full Text] [Related]

  • 15. Pin1 inhibitor Juglone prevents diabetic vascular dysfunction.
    Costantino S, Paneni F, Lüscher TF, Cosentino F.
    Int J Cardiol; 2016 Jan 15; 203():702-7. PubMed ID: 26583846
    [Abstract] [Full Text] [Related]

  • 16. The prolyl isomerase Pin1 interacts with a ribosomal protein S6 kinase to enhance insulin-induced AP-1 activity and cellular transformation.
    Lee NY, Choi HK, Shim JH, Kang KW, Dong Z, Choi HS.
    Carcinogenesis; 2009 Apr 15; 30(4):671-81. PubMed ID: 19168580
    [Abstract] [Full Text] [Related]

  • 17. Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer.
    Ryo A, Liou YC, Lu KP, Wulf G.
    J Cell Sci; 2003 Mar 01; 116(Pt 5):773-83. PubMed ID: 12571275
    [Abstract] [Full Text] [Related]

  • 18. Functional conservation of phosphorylation-specific prolyl isomerases in plants.
    Yao JL, Kops O, Lu PJ, Lu KP.
    J Biol Chem; 2001 Apr 27; 276(17):13517-23. PubMed ID: 11118438
    [Abstract] [Full Text] [Related]

  • 19. Effect of Pin1 inhibitor juglone on proliferation, migration and angiogenic ability of breast cancer cell line MCF7Adr.
    Hu YG, Shen YF, Li Y.
    J Huazhong Univ Sci Technolog Med Sci; 2015 Aug 27; 35(4):531-534. PubMed ID: 26223922
    [Abstract] [Full Text] [Related]

  • 20. Rhein exhibits antitumorigenic effects by interfering with the interaction between prolyl isomerase Pin1 and c-Jun.
    Cho JH, Chae JI, Shim JH.
    Oncol Rep; 2017 Mar 27; 37(3):1865-1872. PubMed ID: 28184937
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.